COBRE Center for Lung Biology Research

Lung disease is the third most frequent cause of death in this country, claiming ~360,000 Americans annually. Tragically, an additional 25 million live with chronic lung diseases, including asthma, emphysema, cancer and cystic fibrosis. Unfortunately, the number of individuals with lung disease is increasing at an alarming rate, thus, a better understanding of the etiology of lung disease and new therapeutics to treat lung disease are required.

The goals of the Dartmouth Lung Biology Center, funded by a COBRE award by the NCRR and NIGMS since 2003 (P20-RR018787/GM103413 and P30-GM106394), are to enhance the research efforts of our faculty and students by:

  1. Integration of the COBRE supported Cores (Host Pathogen Integration Core, Live Cell Imaging Core, and Translational Research Core) with shared services in the Geisel School of Medicine at Dartmouth, Dartmouth Hitchcock Medical Center(DHMC) and other IDeA supported Cores, including Bioinformatics and Biostatistics;

  2. Fostering synergistic scientific collaboration through the COBRE Research Projects, associated Cores, and other basic and translational infrastructure and programs at the Geisel School of Medicine at Dartmouth/DHMC, including the Immunology COBRE, the Bioinformatics COBRE, the Center for Epidemiology COBRE, and the Dartmouth INBRE programs;

  3. Mentoring and supporting the career development of all faculty in the program, and;

  4. Providing administrative support.

Pilot Projects:

Dab2 Inhibitors as Therapeutic Stabilizers of F508-CFTR

Project Leader: Dean Madden, Ph.D.

Microbiological profiles in sputum and in regions of airway damage

Project Leader: Alix Ashare, M.D., Ph.D.
Co-Investigator: Deborah A. Hogan, Ph.D.

Arsenic exposure and airway remodeling after acute influenza infection

Project Leader: Mitsuo Matsuoka, MD, Ph.D.
Co-Investigator: Richard I. Enelow, M.D.

Optimization of a novel compound with activity against MRSA and P. aeruginosa

Project Leader: Ambrose Cheung, M.D.

Development of cFLIP-calmodulin interaction inhibitors for lung cancer therapy

Project Leader: Maria Pellegrini, Ph.D.
Co-Investigator: Dale F. Mierke, Ph.D.

Fungal Metabolic Adaptation and Inflammatory Lung Disease

Project Leader: Robert A Cramer, Ph.D.

Reconstitution of Microbial Communities of CF Infants

Project Leader and Investigator: George A O'Toole, Ph.D.

Analysis and Evasion of Pathogen-derived Lysozyme Inhibitors

Project Leader: Karl E. Griswold, Ph.D.
Co-Investigator: Brent Berwin, Ph.D.

The longitudinal microbiology and immunology of the airway in mechanically ventilated adults

Project Leader: Manuel Vilchez, M.D.
Co-Investigators: Richard Zuckerman, M.D., M.P.H., Harold Manning, M.D., George A O'Toole, Ph.D.

News

2014 Pilot Awards

April 2, 2014

The Dartmouth Lung Biology Center requests applications for Pilot Project Program (P^3) Awards. We seek to fund basic, translational, and clinical research that will advance the understanding and treatment of lung disease, strengthen interdisciplinary faculty interactions, and leverage extramural funding opportunities. For details, please see the RFA announcement. The deadline is April 23, 2014.

Eric Bordeleau receives Kin Canada award from the Canadian Cystic Fibrosis Foundation

March 31, 2014

Eric Bordeleau, who will be joining George O'Toole's lab in September, was awarded the Kin Canada award from the Canadian Cystic Fibrosis Foundation for the top scoring postdoctoral fellowship application this year. In the O'Toole lab, Eric will study the microbiome of CF patients by developing new lab models to study these polymicrobial communities. He is currently a Ph.D. student at the Université de Sherbrooke in Canada.

Manuscript featured in the quarterly CF Literature Update reading list compiled by Gilead Pharmaceuticals

February 20, 2014

The recent publication, "Unique Microbial Communities Persist in Individual Cystic Fibrosis Patients throughout a Clinical Exacerbation", published in the journal Microbiome, was featured in the quarterly CF Literature Update reading list compiled by Gilead Pharmaceuticals. This study was lead by Katie Price, a postdoctoral fellow in the O'Toole lab and was supported by a Cystic Fibrosis Foundation Basbaum Family Postdoctoral Fellowship to Dr. Price. This study represented the efforts of a team of Lung Biology Center members, including Tom Hampton, Alex Gifford, Emily Dolben and Deb Hogan, as well as collaborators Hilary Morrison and Mitch Sogin at the Marine Biological Lab. The central findings of the manuscript include the finding that the microbial structure of each patient's sputum microbiome is distinct and resilient to exacerbation and antibiotic treatment, and that no single organism or group of organisms could be identified that herald the onset of exacerbation.

Events

Weekly Meeting Schedule, 2013-2014

September 16, 2013

The Lung Biology Weekly Meetings have resumed. Please click here to view the schedule.